目的探讨不同类型淋巴瘤血浆白细胞介素6(IL-6)和10(IL-10)的表达以及与临床特征、治疗反应、预后指标的关系。方法采用酶联免疫吸附(ELISA)法测定132例恶性淋巴瘤患者及132例健康对照者血浆IL-6和IL-10浓度。结果不同类型淋巴瘤患者血浆IL-6和IL-10水平均高于健康对照组(P<0.05),不同类型比较除T-NHL组血浆IL-6水平高于B-NHL,差异有统计学意义(P<0.05),其余组间差异皆无统计学意义(P>0.05)。哈萨克族患者IL-6水平高于汉族和维吾尔族;有B症状、IPI高危组、β2-MG、LDH和CRP高水平组血浆IL-6水平高于无B症状、低危组、β2-MG、LDH和CRP低水A平r组bo,r差分异期有Ⅰ统～Ⅱ计、学无意B义症(状P、<β02.-0M5)G。和ACnnR APr低bo水r分平期组Ⅲ,差～Ⅳ异、有有统B计症学状意、β义2-(MPG<和0.0C5)R。P高化水疗平后(C组R)患血者浆IILL--61和0水IL平-1高0水于平An明n显低于PR、PD和未治疗组(P<0.05);血浆IL-10和IL-6及IL-10和β2-MG呈正相关(P<0.05)。结论淋巴瘤患者IL-6和IL-10水平明显高于健康对照组,其水平的高低与肿瘤负荷有关;检测血浆中IL-6和IL-10的水平,可以做为临床淋巴瘤诊断、判断疗效和预后的辅助指标。 Objective To investigate the expressions of interleukin-6 (IL-6) and interleukin-10 (10-IL-10) in different types of lymphoma and their clinical characteristics, treatment response and prognosis. Methods The plasma levels of IL-6 and IL-10 in 132 patients with malignant lymphoma and 132 healthy controls were determined by enzyme linked immunosorbent assay (ELISA). Results The levels of plasma IL-6 and IL-10 in patients with different types of lymphoma were significantly higher than those in healthy controls (P <0.05). The plasma levels of IL-6 in different types of T-NHL patients were higher than those in B-NHL patients (P <0.05), but there was no significant difference among the other groups (P> 0.05). The level of IL-6 in Kazak patients was higher than that in Han and Uygur nationals. In patients with high risk of IPI, the levels of IL-6 in high-risk IPI, β2-MG, LDH and CRP groups were higher than those in non-B, , LDH and CRP low water A level r group bo, r difference between Ⅰ ~ Ⅱ total, no intention of learning B disease (P, <β02.-0M5) G. And ACnnR APr low bo water r staging group Ⅲ, poor ~ Ⅳ different, there are stereotactic B syndrome meaning, β 2 - (MPG